REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New portfolio company Deakin Bio-Hybrid Materials

23 Oct 2023 07:00

RNS Number : 8822Q
Frontier IP Group plc
23 October 2023
 

Reach - a non-regulatory announcement

AIM: FIPP

23 October 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - new portfolio company Deakin Bio-Hybrid Materials

 

Frontier IP, a specialist in commercialising intellectual property, today announces it has taken a 32.8 per cent equity stake in Deakin Bio-Hybrid Materials Limited, ("DeakinBio" or the "Company").

 

DeakinBio has developed a technology, termed BioSintering®, to produce advanced bio-based materials from organic waste such as chickpea broth or algae, along with widely available inorganic powders such as crushed limestone. The bio-based materials have compositions similar to natural materials such as seashells and pearl. Initial applications are as sustainable alternatives to ceramic tiles, with the potential to reduce the carbon footprint of tile manufacture by up to 90 per cent.

 

Traditional ceramic tiles have a high carbon footprint because they need to be fired at high temperatures to harden (sinter) and glaze the products. Making one square metre of tiles can emit up to 16 kg of carbon dioxide. DeakinBio's BioSintering and BioGlazing processes remove the need for firing and glazing, and the ambition is to produce tiles with similar strength and functionality to their conventional equivalents but with a much lower carbon footprint - currently calculated at 0.92 kg of CO2e emissions per square metre according to an independent Life Cycle Assessment. It is intended to make the tiles on industry-standard production lines.

 

BioSintering® and BioGlazing have been used to date to make materials based on the principles of combining biopolymers, water, and calcium carbonate particles to produce a biocomposite material after undergoing low-temperature processing. The inorganic material is currently powdered limestone, although DeakinBio is exploring the use of crushed seashells, a waste product from the seafood industry, as a source of calcium carbonate in the future.

 

The Company's first material, Fabalith®, combines calcium carbonate with a binder made from chickpea broth, a waste product from the food industry.

 

DeakinBio was founded in June 2021 by BioSintering® and BioGlazing inventor Dr Aled Roberts who is based at the Manchester Institute of Biotechnology, University of Manchester where he is a Research Fellow. Dr Roberts holds a PhD in Materials Chemistry from the University of Liverpool. He was lead researcher on the project to create StarCrete® - a new concrete-like material made from extra-terrestrial dust, potato starch and a pinch of salt, which could one day be used to build infrastructure in space.

 

The Company is also exploring the feasibility of new materials made from bio-manufacturing waste streams, such as microbial waste, after winning a £92,364 grant from Innovate UK.

 

DeakinBio won the £50,000 first prize in the University of Manchester's Eli Harari Graphene Enterprise Awards for 2022.

 

With its focus on developing new materials, partly made from organic waste streams, DeakinBio fits into Frontier IP's Materials, and Food and Agritech clusters. It is expected that there will be opportunities for the Company to share expertise with other portfolio companies, including: Alusid, which has developed complementary technology for sustainable building materials using recycled industrial waste, and; Nandi Proteins, which has extensive connections in the food industry and with potential sources of chickpea waste. Alusid's first mass-produced wall tile range, Principle, has recently been launched by Topps Tiles, the UK's no. 1 tile specialist, through its retail outlets.

 

More information is available on the Company's website: https://www.deakinbio.com/

 

 

DeakinBio Founder Dr Aled Roberts said: "We are delighted to be partnering with Frontier IP to help us accelerate the commercialisation of our exciting technologies. With their proven track record of success and expertise in technology transfer, we are confident that this collaboration will help us bring our cutting-edge solutions to the market and create real-world impact."

 

Neil Crabb, Frontier IP Chief Executive Officer, said: "We are excited about the potential of DeakinBio and its novel biocomposites, not just in the tile industry, but in other sectors too. The company fits very well into our Materials, and Food and Agritech clusters and is already sharing expertise and knowledge with other companies in our portfolio. We are looking forward to working with Aled and the DeakinBio team and supporting them to future success. "

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 3968 7815

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLBDGBDDDGXD
Date   Source Headline
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.